IPV at 6 and fIPV at 22 weeks, Rotarix — Competitive Intelligence Brief

IPV at 6 and fIPV at 22 weeks, Rotarix (IPV at 6 and fIPV at 22 weeks, Rotarix) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: vaccine. Area: Immunology.

marketed vaccine Immunology Biologic

Target snapshot

IPV at 6 and fIPV at 22 weeks, Rotarix (IPV at 6 and fIPV at 22 weeks, Rotarix) — Centers for Disease Control and Prevention. IPV (inactivated poliovirus vaccine) and fIPV (fractional dose IPV) stimulate immune responses against poliovirus types 1, 2, and 3, while Rotarix protects against rotavirus infection through live attenuated viral immunization.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
IPV at 6 and fIPV at 22 weeks, Rotarix TARGET	IPV at 6 and fIPV at 22 weeks, Rotarix	Centers for Disease Control and Prevention	marketed	vaccine
Comirnaty	BNT162b2 (tozinameran)	Pfizer Inc.	marketed	vaccine	SARS-CoV-2 virus	2021-08-23
Prevnar 20	pneumococcal 20-valent conjugate vaccine (PCV20)	Pfizer Inc.	marketed	Pneumococcal conjugate vaccine	Streptococcus pneumoniae capsular polysaccharides (20 serotypes)	2021-06-08
FSME-IMMUN Vaccine	FSME-IMMUN Vaccine	Region Örebro County	marketed	Inactivated viral vaccine	Tick-borne encephalitis virus (TBEV)
mRNA-1273 Variant-containing Formulation	mRNA-1273 Variant-containing Formulation	ModernaTX, Inc.	marketed	mRNA vaccine	SARS-CoV-2 spike protein (variant-specific)
Evaluation of vaccines against flu	Evaluation of vaccines against flu	Assistance Publique - Hôpitaux de Paris	marketed	vaccine
Traditional HBV Vaccine	Traditional HBV Vaccine	NYU Langone Health	marketed	vaccine	Hepatitis B surface antigen (HBsAg)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

• 2033-06-01 — Prevnar 20 · US 8,895,024 · Composition of matter · US
• 2035-06-01 — Prevnar 20 · US 10,279,033 · Method of use · US

Sponsor landscape (vaccine class)

1. Pfizer · 20 drugs in this class
2. Sanofi Pasteur, a Sanofi Company · 20 drugs in this class
3. GlaxoSmithKline · 12 drugs in this class
4. Merck Sharp & Dohme LLC · 12 drugs in this class
5. Centers for Disease Control and Prevention · 9 drugs in this class
6. Zhejiang Provincial Center for Disease Control and Prevention · 7 drugs in this class
7. Jiangsu Province Centers for Disease Control and Prevention · 6 drugs in this class
8. Beijing Center for Disease Control and Prevention · 6 drugs in this class
9. International Centre for Diarrhoeal Disease Research, Bangladesh · 5 drugs in this class
10. Sinovac Biotech Co., Ltd · 4 drugs in this class